Results 241 to 250 of about 2,103,612 (328)

Digging into the Cause of Drug-Induced Thrombocytopenia: A Case Report. [PDF]

J Adv Pract Oncol
Pham VA, Selby C.
europepmc   +1 more source

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J.H. Schatorjé, Esther P.A.H. Hoppenreijs, Joost F. Swart, Marc H.A. Jansen, Jorg van Loosdregt, Sebastiaan J. Vastert   +14 more
wiley   +1 more source

Activated platelets stimulate effector CD8+ T cells to enhance HNSCC immunotherapy efficacy. [PDF]

Discov Oncol
Yuan Z, Guo L, Pang Y, Wang W, Shang Y, Xie C, Qian C, Sun J, Wu X.   +8 more
europepmc   +1 more source

Thrombocytopenia and Anemia After Cardiac Surgery

American Journal of Hematology, EarlyView.
Myriam Beshai, Nour Alhomsi, Theodore E. Warkentin   +2 more
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Profound Thrombocytopenia and Dyspnea 11 Days After Cardiac Surgery. [PDF]

Am J Hematol
Vuong S, Pai M, Patterson S, Warkentin TE.   +3 more
europepmc   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

Severe thrombocytopenia is associated with adverse pregnancy outcomes in patients with obstetric antiphospholipid syndrome. [PDF]

Eur J Med Res
Jin J, Zhang M, Cai X, Hou Y, Xiang X, Hou L, Li J, Li C.   +7 more
europepmc   +1 more source

Recent advances of nanomaterials in imaging liver fibrosis

BMEMat, EarlyView.
Schematic summary on the latest strategies of liver fibrosis imaging based on various nanomaterials. Abstract Liver fibrosis is a pathological process resulting from prolonged exposure to various injury factors. It is characterized by the abnormal proliferation and activation of hepatic stellate cells and excessive deposition of extracellular matrix ...
Jin Cui, Shuxuan Zhang, Xueli Xu, Ke Ren, Mengzhen Dong, Zhaokun Nie, Yang Xu, Xiaohui Dai, Peng Xu, Shuo Sun, Xinya Zhao, Xiao Sun   +11 more
wiley   +1 more source